Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation - DTU Orbit (22/03/2019)

**Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation**

**Objectives:** We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark. **Materials and Methods:** In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause. Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n=107/30%) and ongoing substance use (n=61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59–12.91). **Conclusions:** In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.

**General information**

State: Published  
Organisations: Department of Bio and Health Informatics, Disease Intelligence and Molecular Evolution, University of Copenhagen, Aalborg University, Lillebaelt Hospital, University of Southern Denmark, Aarhus University  
Number of pages: 8  
Pages: 849-856  
Publication date: 2018  
Peer-reviewed: Yes  

**Publication information**

Journal: Scandinavian Journal of Gastroenterology  
Volume: 53  
Issue number: 7  
ISSN (Print): 0036-5521  
Ratings:  
BFI (2019): BFI-level 1  
Web of Science (2019): Indexed yes  
BFI (2018): BFI-level 1  
Web of Science (2018): Indexed yes  
BFI (2017): BFI-level 1  
Scopus rating (2017): CiteScore 2.35 SJR 1.226 SNIP 0.91  
Web of Science (2017): Impact factor 2.629  
Web of Science (2017): Indexed yes  
BFI (2016): BFI-level 1  
Scopus rating (2016): CiteScore 2.38 SJR 1.108 SNIP 0.918  
Web of Science (2016): Impact factor 2.526  
BFI (2015): BFI-level 1  
Scopus rating (2015): CiteScore 2.19 SJR 0.947 SNIP 0.764  
Web of Science (2015): Impact factor 2.199  
Web of Science (2015): Indexed yes  
BFI (2014): BFI-level 1  
Scopus rating (2014): CiteScore 2.44 SJR 1.072 SNIP 0.999  
Web of Science (2014): Impact factor 2.361  
BFI (2013): BFI-level 1  
Scopus rating (2013): CiteScore 2.33 SJR 1.08 SNIP 0.987  
Web of Science (2013): Impact factor 2.329  
ISI indexed (2013): ISI indexed yes  
Web of Science (2013): Indexed yes
Keywords: Barriers to treatment, DAA, Direct Acting Antivirals, Factors associated with treatment, HCV, Hepatitis C virus, Liver cancer, Liver disease, Treatment initiation

Original language: English

Keywords: Barriers to treatment, DAA, Direct Acting Antivirals, Factors associated with treatment, HCV, Hepatitis C virus, Liver cancer, Liver disease, Treatment initiation

DOIs: 10.1080/00365521.2018.1467963

Source: Scopus

Source-ID: 85046484571

Research output: Research - peer-review; Journal article – Annual report year: 2018